Subcutaneous Biologics: Clinical Pharmacology and Drug Development
Clinical Pharmacology & Therapeutics · 2024
DOI: 10.1002/cpt.3179 ↗Kurz gefasst
Editorial in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Sihem Ait-Oudhia und 3 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co., Inc., Rahway, New Jersey, USA. Hauptthemen laut MEDLINE: Biological Products, Pharmacology, Clinical. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Merck & Co., Inc., Rahway, New Jersey, USA.
- Genentech Inc, South San Francisco, California, USA.
- Certara, Canterbury, UK.
- University of Leiden, Leiden, The Netherlands.
ORCID-Profile: Sihem Ait-Oudhia, Joseph Chen, Junyi Li
Zitieren
APA
Ait-Oudhia, S., Chen, J., Li, J., & van der Graaf, P. H. (2024). Subcutaneous Biologics: Clinical Pharmacology and Drug Development. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3179
Vancouver
Ait-Oudhia S, Chen J, Li J, van der Graaf PH. Subcutaneous Biologics: Clinical Pharmacology and Drug Development. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3179
BibTeX
@article{AitOudhia2024,
author = {Ait-Oudhia, Sihem and Chen, Joseph and Li, Junyi and van der Graaf, Piet H},
title = {Subcutaneous Biologics: Clinical Pharmacology and Drug Development},
journal = {Clinical Pharmacology & Therapeutics},
year = {2024},
doi = {10.1002/cpt.3179}
}
EUVIMED